JUN 12, 2020 8:12 AM PDT

Reserach on APOBEC3A opens the way for new treatment targets

New research identifies how a protein, APOBEC3A, triggers genetic changes that result in various cancers. This expansion of the understanding that APOBEC3A plays in tumor cells could lead to more effective targeted anti-cancer treatments. 

Photo: Pixabay

The research, entitled, "Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots," was led by scientists from the University of California, Irvine.  Senior investigator Remi Buisson, PhD, is an assistant professor in the Department of Biological Chemistry at the UCI School of Medicine. Buisson commented: 

"Targeting cancer cells with high levels of APOBEC3A protein activities and disrupting, at the same time, the DNA damage response necessary to repair damages caused by APOBEC3A, could be key to more effective cancer therapies. However, to exploit the vulnerability of the cancer cells, it is critical to first quantitatively measure the protein's activity in tumors."

In order to quantify that activity, the researchers developed an assay using hotspot RNA mutations to measure the RNA-editing activity of APOBEC3A in cancer cells. To do so, they utilized droplet digital PCR. 

The implications of this study, which was published in Nature Communications, are significant, say the researchers.

"Our study presents a new strategy to follow the dysregulation of APOBEC3A in tumors, providing opportunities to investigate the role of APOBEC3A in tumor evolution and to target the APOBEC3A-induced vulnerability in therapy," said Buisson. "We anticipate that the RNA mutation-based APOBEC3A assay will significantly advance our understanding of the function of the protein in tumorigenesis and allow us to more effectively exploit the vulnerabilities it creates in cancer therapy."

Sources: Nature Communications, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
MAY 31, 2021
Immunology
Engineering Faster, More Agile T Cell Cancer Fighters
MAY 31, 2021
Engineering Faster, More Agile T Cell Cancer Fighters
Cell therapies use engineered T cells extracted from the patient’s own immune system to rally an attack on tumors. ...
JUL 23, 2021
Cancer
New Drug Eradicates Breast Cancer Tumors in Days
JUL 23, 2021
New Drug Eradicates Breast Cancer Tumors in Days
A new drug can kill between 95 and 100% of cancer cells in mice with human estrogen-receptor-positive breast cancer. The ...
AUG 19, 2021
Cancer
Vitamin D Reduces Risk of Early-Onset Colorectal Cancer
AUG 19, 2021
Vitamin D Reduces Risk of Early-Onset Colorectal Cancer
Colorectal cancer (CRC) is the third most diagnosed type of cancer in both men and women in the United States and CRC in ...
AUG 19, 2021
Cancer
Age of Colorectal Cancer Diagnosis Does not Affect Tumor Growth
AUG 19, 2021
Age of Colorectal Cancer Diagnosis Does not Affect Tumor Growth
Early-onset colorectal cancer progresses in the same way as average onset colorectal cancer. The corresponding study was ...
SEP 02, 2021
Cancer
When Cholesterol Doesn't Kill Cancer, it Makes it Stronger!
SEP 02, 2021
When Cholesterol Doesn't Kill Cancer, it Makes it Stronger!
High cholesterol is associated with an increased risk of several types of cancer, and cancer patients with high choleste ...
OCT 14, 2021
Immunology
'Bio-Betters' Form the Next Wave of Cancer Therapies
OCT 14, 2021
'Bio-Betters' Form the Next Wave of Cancer Therapies
  Antibodies are blood proteins with highly specialized functions: to recognize and eliminate bacteria, viruses, an ...
Loading Comments...